Portolan Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-1,600,902
Closed -$435K – 166
2022
Q3
$435K Sell
1,600,902
-4,697
-0.3% -$2.05K 0.05% 126
2022
Q2
$1.24M Hold
1,605,599
– – 0.12% 120
2022
Q1
$1.72M Buy
1,605,599
+244,895
+18% +$445K 0.14% 121
2021
Q4
$2.58M Buy
1,360,704
+97,283
+8% +$233K 0.17% 107
2021
Q3
$3.8M Sell
1,263,421
-132,946
-10% -$474K 0.28% 100
2021
Q2
$5.46M Sell
1,396,367
-124,538
-8% -$516K 0.39% 90
2021
Q1
$7.71M Buy
1,520,905
+213,178
+16% +$1.11M 0.61% 68
2020
Q4
$5.35M Buy
1,307,727
+6,652
+0.5% +$32.7K 0.49% 77
2020
Q3
$6.32M Buy
1,301,075
+515,088
+66% +$2.81M 0.72% 58
2020
Q2
$4.35M Buy
785,987
+310,191
+65% +$1.42M 0.5% 76
2020
Q1
$1.56M Buy
+475,796
New +$2.51M 0.23% 101

Portolan Capital Management's AGTC Position: Q4 2022 in Review

Portolan Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2022, closing a stake of 1,600,902 shares — an estimated $435K sold.

Portolan Capital Management first reported a position in AGTC in Q1 2020 and held it in 11 quarters. The position peaked at $7.71M in Q1 2021. 0 funds tracked by Wall St. Rank hold AGTC as of Q4 2022.

  • Portolan Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q4 2022 after selling out during the quarter.
  • Portolan Capital Management sold 1,600,902 Applied Genetic Technologies Corporation shares in Q4 2022, an estimated $435K.
  • Portolan Capital Management first reported a position in Applied Genetic Technologies Corporation in Q1 2020 and held it in 11 quarters.
  • Portolan Capital Management's Applied Genetic Technologies Corporation position peaked at $7.71M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2022.

Based on Portolan Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.